Overall Score

Environmental

R&D intensity remains very high at 94.2% of revenue, indicating a science-driven model with meaningful innovation investment.

Capex intensity is elevated at 142.7% of revenue, suggesting continued resource use to support development and operations.

Gross margin is 41.8%, which provides some cushion, but the company is still deeply unprofitable and cash-flow negative.

Social

The company’s business is centered on ophthalmology, supporting a healthcare access and patient-outcome angle.

No recent news was provided indicating major changes in patient access, product adoption, or workforce practices.

Operating losses remain substantial, which can constrain broader stakeholder investment despite the healthcare mission.

Governance

Balance sheet leverage remains modest, with debt-to-equity at 0.13 and current ratio at 4.50, supporting financial flexibility.

Cash and liquidity remain strong relative to near-term obligations, with cash ratio at 2.63 and net debt to EBITDA at 0.30.

Governance is tempered by weak profitability and negative operating cash flow, which keep execution risk elevated.